The main objective of the trial is to find out if 4-hour continuous infusion of parenteral P2Y12 inhibitor cangrelor at the start of primary percutaneous coronary intervention (PCI) immediately and effectively suppresses platelet activity in comatose survivors of out-of-hospital cardiac arrest (OHCA). Half of the participants will receive the standard care of dual antiplatelet therapy - acetysalicylic acid and ticagrelor tablets via nasogastric or orogastric tube and the other half the standard care with additional cangrelor infusion at the start of the PCI.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
VerifyNow P2Y12Test - Platelet Reactivity
Timeframe: 1 hour after the start of cangrelor infusion/1 hour after the start of PPCI in controls
VerifyNow P2Y12Test - Platelet Reactivity
Timeframe: 3 hours after the start of cangrelor infusion/3 hours after the start of PPCI in controls
VerifyNow P2Y12Test - Platelet Reactivity
Timeframe: 5 hours after the start of cangrelor infusion/5 hours after the start of PPCI in controls
Multiplate ADP test
Timeframe: 1 hour after the start of cangrelor infusion/1 hour after the start of PPCI in controls
Multiplate ADP test
Timeframe: 3 hours after the start of cangrelor infusion/3 hours after the start of PPCI in controls
Multiplate ADP test
Timeframe: 5 hours after the start of cangrelor infusion/5 hours after the start of PPCI in controls
BARC score or the need for discontinuation of cangrelor infusion
Timeframe: During the cangrelor infusion and up to 5 hours after the PCI